FindTrial
Sign In

Long-term safety of paclitaxel containing devices in Japan

Patient-level meta-analysis of mortality from paclitaxel-containing device in Japanese patients with symptomatic superficial femoral artery disease. - META-JAPAN

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000041208
Enrollment
2500
Registered
2020-08-04
Start date
2019-12-14
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral artery disease

Interventions

None listed

Sponsors

Toho University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Eligible trials were limited to approved devices as of March 2019 for use in the femoropopliteal artery, had a follow- up period of >1 year, and were conducted in Japan under good clinical practice (GCP) or good post-marketing study practice (GPSP).

Exclusion criteria

Exclusion criteria: Clinical trials 1. not approved device in Japan 2. not conducted under GCP or GPSP guidance

Design outcomes

Primary

MeasureTime frame
cumulative 5year all cause death—

Countries

Japan

Contacts

Public ContactMasato Nakamura

Toho University, Oahshi Medical Center Division of Cardiovascular Medicine

masato@oha.toho-u.ac.jp0334681251

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026